Trials / Unknown
UnknownNCT04038034
Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma
Clinical Evaluation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) 100 mg BID Oral Administration in Patients Affected by Primary Open Angle Glaucoma (POAG): a Randomized, Double Blind Study
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- VISUfarma SpA · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double blind study with competitive enrolment, aimed to enroll a total of 70 patients with a diagnosis of primary open angle glaucoma (POAG). Patients, after signing the Informed Consent, will enter into a 1- week screening phase during which the baseline tests will be conducted. Subjects will be randomized in a 1:1 ratio to the following groups: * group A of 35 patients treated with pressure lowering drugs and placebo; * group B of 35 patients with pressure lowering drugs and COQUN oral formulation 100 mg BID.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | CoQ10- MINIACTIVES | COQUN oral formulation 100 mg BID |
| DIETARY_SUPPLEMENT | Placebo | Placebo |
Timeline
- Start date
- 2019-09-01
- Primary completion
- 2021-08-30
- Completion
- 2021-08-30
- First posted
- 2019-07-30
- Last updated
- 2020-04-28
Locations
2 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT04038034. Inclusion in this directory is not an endorsement.